Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
01 August 2016Website:
http://quoinpharma.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
QNRX Latest News
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will be a Bronze Sponsor for the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 national conference in Albuquerque, New Mexico from June 28-30, 2024.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced today that it will be releasing its financial results for the first quarter of 2024 on Thursday, May 9, 2024 before the market opens.
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its fourth quarter and 2023 financial results after the market closes on Wednesday, March 13, 2024.
Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is falling on Tuesday after the clinical-stage specialty pharmaceutical company announced details of a public offering for its shares. The public offering has Quoin Pharmaceuticals selling 4,062,500 shares of QNRX stock for $1.60 each.
Quoin Pharmaceuticals, Ltd. (QNRX) Q3 2023 Earnings Call Transcript
ASHBURN, Va., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2023 financial results after the market closes on Wednesday, November 8, 2023.
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX ) Q2 2023 Results Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Gordon Dunn - Chief Financial Officer Michael Myers - Co-Founder, Chairman and Chief Executive Officer Conference Call Participants Naz Rahman - Maxim Group Laura Suriel - Alliance Global Partners Operator Good morning.
Quoin Pharmaceuticals (NASDAQ: QNRX ) stock is taking a massive beating on Monday as the company prepares for an ADS ratio change. According to a filing from Quoin Pharmaceuticals, the company is enacting an ADS ratio change that will switch its stock from one for 5,000 shares to one for 6,000 shares.
What type of business is Quoin Pharmaceuticals?
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
What sector is Quoin Pharmaceuticals in?
Quoin Pharmaceuticals is in the Healthcare sector
What industry is Quoin Pharmaceuticals in?
Quoin Pharmaceuticals is in the Biotechnology industry
What country is Quoin Pharmaceuticals from?
Quoin Pharmaceuticals is headquartered in United States
When did Quoin Pharmaceuticals go public?
Quoin Pharmaceuticals initial public offering (IPO) was on 01 August 2016
What is Quoin Pharmaceuticals website?
https://quoinpharma.com
Is Quoin Pharmaceuticals in the S&P 500?
No, Quoin Pharmaceuticals is not included in the S&P 500 index
Is Quoin Pharmaceuticals in the NASDAQ 100?
No, Quoin Pharmaceuticals is not included in the NASDAQ 100 index
Is Quoin Pharmaceuticals in the Dow Jones?
No, Quoin Pharmaceuticals is not included in the Dow Jones index
When does Quoin Pharmaceuticals report earnings?
The next expected earnings date for Quoin Pharmaceuticals is 02 August 2024